PT3114214T - Métodos de reprogramação melhorados e plataformas de cultura celular - Google Patents

Métodos de reprogramação melhorados e plataformas de cultura celular

Info

Publication number
PT3114214T
PT3114214T PT157577537T PT15757753T PT3114214T PT 3114214 T PT3114214 T PT 3114214T PT 157577537 T PT157577537 T PT 157577537T PT 15757753 T PT15757753 T PT 15757753T PT 3114214 T PT3114214 T PT 3114214T
Authority
PT
Portugal
Prior art keywords
cell culture
reprogramming methods
culture platforms
improved reprogramming
improved
Prior art date
Application number
PT157577537T
Other languages
English (en)
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of PT3114214T publication Critical patent/PT3114214T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
PT157577537T 2014-03-04 2015-03-04 Métodos de reprogramação melhorados e plataformas de cultura celular PT3114214T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04

Publications (1)

Publication Number Publication Date
PT3114214T true PT3114214T (pt) 2024-01-03

Family

ID=54055848

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157577537T PT3114214T (pt) 2014-03-04 2015-03-04 Métodos de reprogramação melhorados e plataformas de cultura celular

Country Status (10)

Country Link
US (2) US11268069B2 (pt)
EP (3) EP3604499A1 (pt)
JP (6) JP6722108B2 (pt)
KR (3) KR102340553B1 (pt)
CN (1) CN106414721A (pt)
AU (2) AU2015227184B2 (pt)
CA (1) CA2941004A1 (pt)
PT (1) PT3114214T (pt)
SG (2) SG10201807292YA (pt)
WO (1) WO2015134652A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
KR102340553B1 (ko) 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
CA2974381A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3324982A4 (en) 2015-07-21 2019-01-09 The Children's Medical Center Corporation HEMATOPOIETIC STEM CELLS EXPRESSING PD-L1 AND USES
AU2016338680B2 (en) * 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
CN108291197B (zh) * 2015-10-21 2022-09-16 印第安纳大学研究与技术公司 生成人内耳感觉上皮和感觉神经元的方法
WO2017078807A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
WO2017123789A1 (en) * 2016-01-12 2017-07-20 Lonza Walkersville, Inc. Methods and vectors to produce vector free induced pluripotent stem cells
CA3048379A1 (en) * 2016-12-27 2018-07-05 Sumitomo Chemical Company, Limited Evaluation method and selection method for induced pluripotent stem cells, and production method for induced pluripotent stem cells
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
AU2018348142A1 (en) * 2017-10-11 2020-04-02 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
IL309585A (en) 2017-12-22 2024-02-01 Fate Therapeutics Inc Enhanced effector training cells and their use
CN111511902A (zh) * 2017-12-28 2020-08-07 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 通过crispr激活生成诱导性多能细胞
EP3768827A1 (en) * 2018-03-22 2021-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for reprogramming somatic cells
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
CN113646424A (zh) * 2019-03-29 2021-11-12 富士胶片株式会社 具有分化成特定细胞的能力的多能干细胞的制造方法及其应用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
EP4073234A1 (en) * 2019-12-11 2022-10-19 Repairon GmbH Expansion of stem cells in suspension in a bioreactor
EP4168536A1 (en) * 2020-06-22 2023-04-26 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
JP2023544324A (ja) * 2020-10-02 2023-10-23 フェイト セラピューティクス，インコーポレイティド 人工多能性幹細胞のための改善されたリプログラミング、維持及び保存
US20230302044A1 (en) * 2022-03-28 2023-09-28 Steve Reilly Composition to increase cellularlongevity

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE194977T1 (de) 1991-09-06 2000-08-15 Yoshitomi Pharmaceutical 4-amino(alkyl)cyclohexan-1-carboxamidverbindung n und ihre verwendung
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
KR100576148B1 (ko) 1996-08-12 2006-05-03 미쯔비시 웰 파마 가부시키가이샤 Ｒｈｏ 키나아제 억제제를 함유하는　약제
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
ES2321462T3 (es) 1997-05-07 2009-06-05 Pharma Mar, S.A. Uso de aplidina para el tratamiento de enfermedades cardiovasculares.
AU749465B2 (en) 1997-06-13 2002-06-27 Japanese Foundation For Cancer Research Smad6 and uses thereof
PT993439E (pt) 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
AU773012B2 (en) 1998-07-24 2004-05-13 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the TGF-beta family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
AU6865100A (en) 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
EE05450B1 (et) 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
WO2008108741A1 (en) 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
DE60218138T2 (de) 2001-03-23 2007-09-20 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
MXPA03008658A (es) 2001-03-23 2005-04-11 Bayer Ag Inhibidores de rho-cinasa.
CA2446110C (en) 2001-05-01 2013-06-25 National Research Council Of Canada A system for inducible expression in eukaryotic cells
CA2461185A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
EP1470122B1 (en) 2002-01-23 2007-12-19 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
CA2473510A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
AU2003210405A1 (en) 2002-03-05 2003-09-16 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
PT3000810T (pt) 2002-03-13 2017-10-25 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
US20050182040A1 (en) 2002-04-03 2005-08-18 Naonori Imazaki Benzamide derivatives
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
CA2503646C (en) 2002-10-28 2011-09-27 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
MXPA05003431A (es) 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
US20060222657A1 (en) 2003-06-20 2006-10-05 Dowdy Steven F Polypeptide transduction and fusogenic peptides
CN103602633A (zh) 2003-10-03 2014-02-26 福田惠一 由干细胞分化诱导心肌细胞的方法
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
KR20070030164A (ko) 2003-10-16 2007-03-15 더 유니버시티 코트, 더 유니버시티 오브 에딘버러 Ｅｓ 세포 자가 재생 및 계통 지정의 조절, 및 이를 위한배지
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
US7772234B2 (en) 2003-11-19 2010-08-10 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
WO2005108416A2 (en) 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and their use
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
DK1922307T3 (da) 2005-05-18 2012-04-02 Array Biopharma Inc Heterocykliske inhibitorer af MEK og fremgangsmåder til anvendelse heraf
MX2008001709A (es) 2005-08-01 2008-11-26 Nupotential Inc Produccion de celulas reprogramadas con potencial restablecido.
CA2621161A1 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
NZ569530A (en) 2005-12-13 2011-07-29 Univ Kyoto Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
JPWO2007088651A1 (ja) 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
WO2007113505A2 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
SE534150C2 (sv) 2006-05-02 2011-05-10 Wisconsin Alumni Res Found Förfarande för differentiering av stamceller till celler av den endodermala och pankreatiska utvecklingslinjen
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
CN101563449A (zh) 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
US7892830B2 (en) 2007-01-17 2011-02-22 Wisconsin Alumni Research Foundation Clonal culture of human pluripotent stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
CN101641436A (zh) 2007-01-30 2010-02-03 佐治亚大学研究基金会 用于产生内胚层和中胚层细胞系及多能游走细胞（mmc）的早期中胚层细胞即稳定的中内胚层细胞群
EP2132225A4 (en) 2007-02-27 2010-06-09 Procell Therapeutics Inc COMBINED USE OF NANOG AND OCT4 PERMEABLE TO CELLS TO INCREASE SELF-RENEWAL AND DELETE DIFFERENTIATION OF STEM CELLS
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
ES2530370T5 (es) 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US8815585B2 (en) 2007-06-29 2014-08-26 Cellular Dynamics International, Inc. Automated method and apparatus for embryonic stem cell culture
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
CA2660123C (en) 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
US20110033931A1 (en) 2007-11-29 2011-02-10 Children's Hospital Of Orange County De-differentiation of human cells
EP2227241A1 (en) 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
AU2008329563A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Oct4 protein
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
EP2279243B1 (en) 2008-03-17 2016-01-06 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
CN101848994A (zh) 2008-07-30 2010-09-29 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
JP5390624B2 (ja) 2008-11-04 2014-01-15 バイアサイト インク 幹細胞集合体懸濁液組成物、その分化方法
BRPI0922345B1 (pt) 2008-12-03 2022-03-22 The Scripps Research Institute Composto, métodos in vitro para estabilizar uma célula animal isolada e para manter a sobrevivência da célula, e, composição
CA2747398C (en) 2008-12-17 2023-06-20 The Scripps Research Institute Generation and maintenance of stem cells
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
CA2758003A1 (en) 2009-04-13 2010-10-21 The Regents Of The University Of California Methods and compositions for stem cell cultures
SG176222A1 (en) 2009-05-27 2011-12-29 Salk Inst For Biological Studi Generation of genetically corrected disease-free induced pluripotent stem cells
EP2438159B1 (en) 2009-05-29 2018-10-03 Kyoto University Method for selecting clone of induced pluripotent stem cells
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
JP5376478B2 (ja) 2009-08-07 2013-12-25 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
KR101874463B1 (ko) 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
CA2777710C (en) 2009-11-04 2021-02-23 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
ES2932664T3 (es) 2009-11-12 2023-01-23 Technion Res & Dev Foundation Medios de cultivo, cultivos celulares y métodos de cultivo de células madre pluripotentes en estado no diferenciado
EP2526189B1 (en) 2010-01-22 2016-10-12 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
US20130011918A1 (en) 2010-02-17 2013-01-10 Biotime Inc. Methods for telomere length and genomic dna quality control and analysis in pluripotent stem cells
ES2533581T3 (es) 2010-03-05 2015-04-13 Texas Heart Institute ETS2 y Mesp1 generadores de progenitores cardíacos a partir de fibroblastos
WO2011123572A1 (en) 2010-03-31 2011-10-06 The Scripps Research Institute Reprogramming cells
WO2011158852A1 (ja) 2010-06-15 2011-12-22 国立大学法人東京大学 誘導型多能性幹細胞の製造方法
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CA2858069C (en) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
JP6164746B2 (ja) 2012-05-22 2017-07-19 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
KR102340553B1 (ko) 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
JP6928604B2 (ja) 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変

Also Published As

Publication number Publication date
SG11201606934SA (en) 2016-09-29
CA2941004A1 (en) 2015-09-11
WO2015134652A1 (en) 2015-09-11
JP2023126627A (ja) 2023-09-07
AU2015227184B2 (en) 2021-05-20
US11268069B2 (en) 2022-03-08
JP2022082668A (ja) 2022-06-02
JP7170600B2 (ja) 2022-11-14
EP3805369A1 (en) 2021-04-14
KR20220147728A (ko) 2022-11-03
AU2015227184A1 (en) 2016-09-15
SG10201807292YA (en) 2018-09-27
EP3114214B1 (en) 2023-11-01
JP2021000107A (ja) 2021-01-07
AU2021218109A1 (en) 2021-09-09
US20170073643A1 (en) 2017-03-16
KR102460549B1 (ko) 2022-10-28
KR102340553B1 (ko) 2021-12-21
EP3604499A1 (en) 2020-02-05
JP6722108B2 (ja) 2020-07-15
JP2019187454A (ja) 2019-10-31
JP2018086018A (ja) 2018-06-07
EP3114214A1 (en) 2017-01-11
EP3114214A4 (en) 2017-08-09
JP2017506904A (ja) 2017-03-16
US20220228125A1 (en) 2022-07-21
KR20160130260A (ko) 2016-11-10
CN106414721A (zh) 2017-02-15
KR20210111884A (ko) 2021-09-13

Similar Documents

Publication Publication Date Title
SG11201606934SA (en) Improved reprogramming methods and cell culture platforms
EP3472301C0 (en) CELL CULTURE DEVICE AND METHODS
LU92752B1 (en) Cell culture apparatus and culture methods using same
SG11201703493SA (en) Cell culture insert
SG11201609916RA (en) Culture method and cell mass
HK1255101A1 (zh) 用於得到調節性t細胞的方法及其用途
SG11201705853VA (en) Cell culture device and cell culture method
EP3124589A4 (en) Cell culture method and cell culture system
GB201611982D0 (en) Cell culture
EP3115450A4 (en) Cell culture method and cell culture device
EP3196292A4 (en) Cell culture apparatus and method
HK1247232A1 (zh) 細胞和組織培養容器
SG11201706090SA (en) Cell culturing method and kit
EP3107996A4 (en) Tscm cells and methods for use
SG11202004935UA (en) Cell culture methods
RS63284B1 (sr) Ćelijska kultura
SG11201702897WA (en) Cell culture bag and cell culture method
PL3865563T3 (pl) Materiały i sposoby do przedłużania pożywki do hodowli komórkowej
IL270880A (en) Cell culture methods
EP3235902A4 (en) Cell culture method and cell culture device
PL3132020T3 (pl) Naczynie do hodowli komórek i jego zastosowanie
EP3192295A4 (en) Method and arrangement for cell combination
PL3287521T3 (pl) Hodowla komórkowa
GB201418980D0 (en) Cell assay kit and method
TWI563082B (en) Cell culture device